^
    1d
    Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=60, Recruiting, Inhye Ahn | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Apr 2024
    Enrollment open • Trial initiation date
    |
    Gazyva (obinutuzumab) • Jaypirca (pirtobrutinib)
    2d
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2/3, N=226, Not yet recruiting, Beijing InnoCare Pharma Tech Co., Ltd.
    New P2/3 trial • Combination therapy
    |
    Yinuokai (orelabrutinib)
    3d
    MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases. (PubMed, Diagn Pathol)
    MNDA was highly expressed in MZL with a potential utility in differential diagnosis between MZL and RLH as well as FL, whereas its value in distinguishing MZL from MCL, CLL/SLL is limited. In addition, MNDA expression in DLBCL was more frequently seen in the non-GCB group and the BCL2/MYC double-expression group, and demonstrated a correlation with CD5, which deserves further investigation. The clinical relevance of MNDA and its correlation with the prognosis of these lymphomas also warrant to be fully elucidated.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD5 (CD5 Molecule)
    |
    BCL2 expression • MYC expression
    3d
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024. (PubMed, J Natl Compr Canc Netw)
    Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent's toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • TP53 mutation + Chr del(17p) • IGH mutation
    |
    Venclexta (venetoclax)
    8d
    Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting. (PubMed, JCO Oncol Pract)
    Venetoclax was associated with total monthly cost savings versus BTKis, illustrating the economic value of time-limited venetoclax-based regimens in the 2L setting.
    Journal • Real-world evidence • Real-world
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax)
    8d
    A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. (clinicaltrials.gov)
    P3, N=344, Recruiting, Ascentage Pharma Group Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • Leukeran (chlorambucil) • lisaftoclax (APG-2575) • fludarabine IV
    8d
    MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    8d
    MAJIC: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P3, N=607, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    13d
    Assessment and prognostic significance of a serum cytokine panel in diffuse large B‑cell lymphoma. (PubMed, Oncol Lett)
    It was also found that raised serum IL-6 and IL-10 levels, together with reduced levels of IL-17, were associated with survival of <1 year in patients with DLBCL (P<0.05), although no significant link was found between cytokine levels and long-term overall survival. In conclusion, the serum levels of IL-6, IL-10, IL-17, TNF-α and IFN-γ can potentially serve as biological indicators of DLBCL tumor immune status, and combined application with the IPI score can be a robust prognostic indicator in patients with DLBCL.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL4 (Interleukin 4) • CRP (C-reactive protein)
    |
    IL10 elevation
    19d
    BRUIN CLL-313: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P3, N=250, Active, not recruiting, Loxo Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • bendamustine
    19d
    A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies (clinicaltrials.gov)
    P3, N=0, Withdrawn, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=200 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Rituxan (rituximab) • cyclophosphamide • Zydelig (idelalisib) • Breyanzi (lisocabtagene maraleucel) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)
    19d
    BGB-16673-101: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=466, Recruiting, BeiGene | N=291 --> 466
    Enrollment change
    |
    BGB-16673
    21d
    CAPTIVATE: Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (clinicaltrials.gov)
    P2, N=323, Completed, Pharmacyclics LLC. | Active, not recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    23d
    Diverse B-cell tumors associated with t(14;19)(q32;q13)/IGH::BCL3 identified by G-banding and fluorescence in situ hybridization. (PubMed, J Clin Exp Hematop)
    The 5 cases shared IGHV preferentially used in B-CLL cells, but the genes were unmutated in 2 B-CLL/SLL cases and significantly mutated in the remaining 3. B-cell tumors with t(14;19)(q32;q13) can be divided into B-CLL/SLL and DLBCL groups, and the anatomy of IGH::BCL3 in the latter may be different from that of the former.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL3 (BCL3 Transcription Coactivator)
    |
    MYC expression
    23d
    ALPINE: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=652, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
    28d
    Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Inhye Ahn
    New P2 trial
    |
    Gazyva (obinutuzumab) • Jaypirca (pirtobrutinib)
    29d
    EPCORE NHL-1: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=666, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | Trial completion date: Apr 2029 --> Jan 2029
    Enrollment closed • Trial completion date
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp)
    29d
    BRUIN: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
    P1/2, N=860, Active, not recruiting, Loxo Oncology, Inc. | Trial completion date: Apr 2024 --> Jan 2028 | Trial primary completion date: Apr 2024 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
    1m
    B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV
    1m
    NKX019-101: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (clinicaltrials.gov)
    P1, N=150, Recruiting, Nkarta Inc. | Trial primary completion date: Dec 2023 --> Aug 2024
    Trial primary completion date
    |
    cyclophosphamide • NKX019
    1m
    A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. (clinicaltrials.gov)
    P3, N=344, Not yet recruiting, Ascentage Pharma Group Inc.
    New P3 trial • Combination therapy
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • Leukeran (chlorambucil) • lisaftoclax (APG-2575) • fludarabine IV
    1m
    Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation (clinicaltrials.gov)
    P2, N=37, Completed, M.D. Anderson Cancer Center | N=72 --> 37
    Enrollment change
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib)
    1m
    Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis. (PubMed, Clin Lymphoma Myeloma Leuk)
    The combination of ofatumumab, HDMP, and lenalidomide was effective and relatively well tolerated in treatment-naive CLL/SLL. Its role in the frontline setting remains unclear given the current available and effective treatment options.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    Chr del(11q)
    |
    lenalidomide • Arzerra (ofatumumab)
    1m
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1m
    A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=85, Recruiting, BeiGene
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447
    1m
    BELLWAVE-001: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (clinicaltrials.gov)
    P1/2, N=190, Active, not recruiting, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BTK mutation • BCL6 translocation • BTK C481
    |
    nemtabrutinib (MK-1026)
    1m
    A Case Crossover Study of Intermittent Fasting in CLL/SLL (clinicaltrials.gov)
    P=N/A, N=6, Completed, British Columbia Cancer Agency | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • CRP (C-reactive protein)
    2ms
    Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, University of Rochester | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> May 2023
    Trial completion date • Trial primary completion date
    |
    Calquence (acalabrutinib) • Rituxan Hycela (rituximab/hyaluronidase)
    2ms
    COVALENT-101: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (clinicaltrials.gov)
    P1, N=177, Recruiting, Biomea Fusion Inc. | Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    BMF-219
    2ms
    Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov)
    P1, N=2, Terminated, OHSU Knight Cancer Institute | Active, not recruiting --> Terminated; Low accrual
    Trial termination
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Venclexta (venetoclax) • Lynparza (olaparib) • Mekinist (trametinib) • erlotinib • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • sorafenib • Rozlytrek (entrectinib) • imatinib • Sutent (sunitinib) • everolimus • Nerlynx (neratinib) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Lorbrena (lorlatinib) • Lenvima (lenvatinib) • bortezomib • doxorubicin hydrochloride • capecitabine • Verzenio (abemaciclib) • Xtandi (enzalutamide capsule) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Stivarga (regorafenib) • abiraterone acetate • oxaliplatin • Aliqopa (copanlisib) • Vizimpro (dacomitinib) • Zydelig (idelalisib) • daunorubicin • Zolinza (vorinostat) • Idhifa (enasidenib) • Farydak (panobinostat) • Erivedge (vismodegib) • Nubeqa (darolutamide) • bicalutamide • leucovorin calcium • cabazitaxel • Vesanoid (tretinoin) • fluorouracil topical
    2ms
    A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P1, N=80, Not yet recruiting, AbbVie
    New P1 trial • Adverse events
    |
    Gazyva (obinutuzumab) • ABBV-453
    2ms
    B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Mayo Clinic | Initiation date: Jan 2024 --> Jun 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV
    2ms
    NCI-2023-08755: Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Northwestern University | N=29 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Opdivo (nivolumab) • Venclexta (venetoclax) • Rituxan (rituximab) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar)
    2ms
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Jan 2025 --> Jan 2026
    Trial completion date • Metastases
    |
    BCL2 expression
    |
    BP1002
    2ms
    Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1, N=36, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Promune (agatolimod)
    2ms
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Active, not recruiting, Acerta Pharma BV | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Apr 2026
    Phase classification • Trial completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    2ms
    Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    Calquence (acalabrutinib)
    2ms
    Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL (clinicaltrials.gov)
    P1, N=35, Recruiting, Ascentage Pharma Group Inc. | Trial completion date: Jan 2023 --> Jun 2026 | Trial primary completion date: Dec 2022 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    lisaftoclax (APG-2575)
    2ms
    Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Copiktra (duvelisib) • ETP-47187
    2ms
    Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    lenalidomide • Blincyto (blinatumomab)
    2ms
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    2ms
    PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (clinicaltrials.gov)
    P1, N=21, Terminated, Prelude Therapeutics | N=132 --> 21 | Trial completion date: Nov 2025 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: May 2025 --> Jan 2024; Company Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    Venclexta (venetoclax) • azacitidine